Comparing two hormone medicines for pain from endometriosis
Compares an implant of gestrinone with oral dienogest in women with endometriosis.
Plain-language title generated from the registry record
Registry title: Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis
Key facts
- Where
- Campina Grande, Rio de Janeiro, São José dos Campos, and São Paulo, BrazilSee the 4 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06543550, who can take part
Where in Brazil
- Instituto Longevite Servicos Medicos LTDACampina Grande, BrazilTaking people
- Nutrindo Ideiais Rio de JaneiroRio de Janeiro, BrazilTaking people
- Jpml Clinica Medica LTDASão José dos Campos, BrazilTaking people
- Nutrindo Ideiais São PauloSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bio Meds Pharmaceutica Ltda
- Trial code
- NCT06543550
- Record updated
- 20 October 2026
- Original description
This study aims to evaluate the effects of therapy with implantable Gestrinone compared to oral Dienogest in relieving complaints related to endometriosis.Read full original descriptionShow less
Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis: Randomized Controlled Clinical Trial
This study aims to evaluate the effects of therapy with implantable Gestrinone compared to oral Dienogest in relieving complaints related to endometriosis.
Inclusion: Adult female patients of menstrual age, pre-menopause (18 to 45 years old), who seek medical treatment to alleviate complaints related to endometriosis, who are not undergoing other therapies to treat them; Patients must have a diagnosis of Grade 1 or 2 endometriosis assessed by imaging tests (ultrasound with bowel preparation and/or MRI of the pelvis with bowel preparation)14, have a BMI of up to 25kg/m2, and weigh between 50 and 70kg.
Exclusion: Patients using medications that may interfere with androgen metabolism within 4 weeks of screening or during the study; Patient who are scheduled for surgical treatment during the study period; Patients with a history of liver disease, cardiovascular disease (myocardial infarction, unstable angina or heart failure), active hepatitis, liver neoplasia or renal failure; Pregnant patients (supporting test must be presented); Breastfeeding women, using other hormonal contraceptive methods or copper or silver IUDs, who have polycystic ovaries, and/or hyperandrogenism.